Stockscreener 앱 받기
232.27
1.40%
-3.29
시간 외 거래:
232.27
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Piper Sandler Reiterates Overweight Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis - Seeking Alpha
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study - Yahoo Finance
LMR Partners LLP Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment - Clinical Trials Arena
Alnylam's Nucresiran Achieves 96% TTR Reduction in Phase 1 ATTR Amyloidosis Trial | ALNY Stock News - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $294.50 Consensus Price Target from Analysts - MarketBeat
Alnylam Pharmaceuticals Enters Oversold Territory (ALNY) - Nasdaq
Primary Hyperoxaluria Treatment Market Outlook by Examining - openPR
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 23.6% in October - MarketBeat
Alnylam Says It's Not A 'Patent Troll' In Vax IP Row - Law360
FMR LLC Expands Stake in Alnylam Pharmaceuticals - GuruFocus.com
Alnylam downgraded at Wolfe on doubts over Amvuttra growth - MSN
Alnylam Pharmaceuticals To Present At UBS Global Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq
Baillie Gifford & Co. Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wolfe Research - MarketBeat
Los Angeles Capital Management LLC Has $37.68 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Trading (ALNY) With Integrated Risk Controls - Stock Traders Daily
5,283 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by New York State Teachers Retirement System - MarketBeat
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Benzinga
Wellington Management Group LLP's Strategic Reduction in Alnylam Pharmaceuticals Inc - GuruFocus.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by AIA Group Ltd - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of Alaska Department of Revenue - MarketBeat
What is HC Wainwright's Forecast for ALNY FY2024 Earnings? - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
Upcoming Opportunities in Hereditary Amyloidosis Market: - openPR
Asset Management One Co. Ltd. Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Van ECK Associates Corp Sells 3,539 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Hemoglobinopathies Market Growth Analysis: Industry - openPR
Alnylam's SWOT analysis: biotech stock poised for growth in ATTR-CM market - Investing.com
Alnylam launches Phase 1 trial of ALN-HTT02 for Huntington’s - Huntington's Disease News
New York State Common Retirement Fund Sells 3,724,457 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. Promotes Cynthia Clayton to Vice President of Investor Relations and Corporate Communications - Marketscreener.com
Alnylam shares remain Buy-rated at H.C. Wainwright, target held steady amid ATTR-CM updates - Investing.com UK
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Boosted by Wealth Enhancement Advisory Services LLC - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN
Silvant Capital Management LLC Has $4.45 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Earnings: Demand for Amvuttra Drives Sales; Vutrisiran Regulatory Application Submitted - Morningstar
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript - MSN
Needham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
AustralianSuper Pty Ltd Invests $1 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlig - GuruFocus.com
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight - Yahoo Finance
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus.com
Earnings call: Alnylam reports strong growth and pipeline progress - Investing.com
Earnings call: Alnylam reports strong growth and pipeline progress By Investing.com - Investing.com UK
Alnylam Pharmaceuticals (LTS:0HD2) Financial Strength : 5 (As of Jun. 2024) - GuruFocus.com
0.65%
0.81%
자본화:
|
볼륨(24시간):